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so the Editor: In 1986, the National Institutes of Health (NIH)
stablished a policy for the inclusion of women in clinical research
hat was subsequently enacted into public law when Congress
pproved the NIH Revitalization Act of 1993 (1). This Act states
hat women and minorities must be included in phase 3 clinical
rials in numbers adequate to allow for valid analyses of differences
n intervention effect. To evaluate the impact of these legislative
eforms, we sought to describe the enrollment of women in
ederally funded cardiovascular (CV) randomized controlled trials
RCTs) during the past 10 years by searching the NIH registry of
linical trials for phase 3 or 4 CV RCTs funded by the National
eart, Lung, and Blood Institute (NHLBI). Studies with primary
utcomes of myocardial infarction, stroke, or death published
etween 1997 and 2006 were included. Trials were excluded if they
ere still recruiting as of November 16, 2006, included children, or
ere restricted to women. We categorized the trials by disease
rocess, the acuity of the patient at study enrollment, and the risk
f the intervention. The categories of disease were coronary artery
isease (CAD), electrophysiologic disease, congestive heart failure
CHF), and hypertension. Acute trials enrolled patients during the
cute phase of illness. High-risk studies involved an invasive
rocedure. Relationships between the mean proportion of women
percent of women) enrolled and the categories described above
ere compared with the Student t test (  0.05) and one-way
nalysis of variance. The mean percent of women enrolled by
isease process was then compared with the percent of women in
he general population age 20 years with the disease process as
eported by the American Heart Association (AHA) Heart Dis-
ase and Stroke Statistics report (2). Gender-specific prevalence
ata were not available from the AHA report for sudden cardiac
eath. Thus, data from the AVID (Antiarrhythmics Vs Implant-
ble Defibrillators) (3) and MUSTT (Multicenter Unsustained
achycardia Trial) (4) registry papers and a large population-based
etrospective cohort study of all out-of-hospital cardiac arrests in
eattle and neighboring King County, Washington (5), were used.
tata software (LP Intercooled Stata, version 9.0, Stata Corpora-
ion, College Station, Texas) was used for statistical analyses.
Of 11,918 NIH studies, 1,488 were funded by the NHLBI. Of
hese, 982 studied CV disease and 851 were no longer recruiting at
he query date. After excluding trials that were not phase 3 or 4
CTs performed in adults, 141 remained, of which 53 reported
rimary outcomes of stroke, myocardial infarction, or death. We
xcluded 3 trials that were restricted to women and 31 published
utside of the time window. This resulted in 19 RCTs (Online
able): 8 CAD, 7 electrophysiologic disease, 3 CHF, and 1
ypertension (Fig. 1). The enrollment of women ranged from 10% uo 47%. The mean enrollment of women for all trials was 27%.
nly 13 trials explicitly presented subgroup analyses based on
ender in the primary report. All studies were published in
igh-impact journals, and many have been cited in major societal
uidelines.
There was no significant difference in the mean percent of
omen enrolled by type of disease, acuity, or risk of intervention
all p  NS). Comparison of the mean percent of women enrolled
n CV RCTs by disease category with the published percent of
omen among those with disease according to the AHA report (2)
howed that enrollment in CAD (29% vs. 46%), CHF (23% vs.
0%), sudden cardiac death (17% vs. 16% in MUSTT registry [4],
3% in AVID registry [3], and 32% in Seattle/King EMS study
5]), and atrial fibrillation (39% vs. 59%) fell short of the
omparative proportions. The mean percent of women enrolled in
ll trials was 27% versus 53% of all patients with CVD who are
omen (2).
Despite a federal mandate for significant inclusion of women in
ederally sponsored clinical trials, women are under-represented in
IH-supported CV RCTs. This lack of legislative impact was first
eported more than a decade ago (6). Our current study of CV
CTs published in the past decade shows an ongoing lack of
rogress in the enrollment of women. We excluded 3 gender-
pecific CV RCTs (7–9) that otherwise were eligible for inclusion
or 2 reasons. First, previous work (6) demonstrating an increase in
he enrollment of women in CV clinical trials funded by the
HLBI between 1965 and 1998 found that this increase was
argely due to the inclusion of the Women’s Health Study (9) and
he Women’s Health Initiative (7). When excluded, the enroll-
ent of women decreased from 54% to 38% with no significant
ncrease in enrollment over time. Thus, the relevant question to be
nswered by our updated analysis was whether the proportion of
nrollment in mixed-gender trials has improved.
Second, the stated goal of the NIH Revitalization Act is to
ensure that the trial is designed and carried out in a manner
ufficient to provide for valid analysis of whether the variables
eing studied in the trial affect women or members of minority
roups, as the case may be, differently than other subjects in the
rial” (1). The existence of 3 large single-gender studies (2
valuating hormone-replacement therapy) does not substitute for
he spirit of the mandate, and although they are important, these
tudies cannot be expected to answer the breadth of questions that
rise in the care of women with heart disease.
The inadequate proportion of women enrolled in NIH-
ponsored CV RCTs merits attention. Although this mission falls
nder the responsibility of the NIH, the lack of success in
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August 19, 2008:672–5ncreasing female participation does not seem to be due to a lack of
urpose. In our experience, enrollment of women and minorities is
mphasized at every stage of trial conduct, from protocol design to
rant approval to scrutiny of periodic enrollment reports with the
tudy leadership. In fact, the enrollment of women in overall NIH
rials has increased significantly since 1993 such that more women
han men were enrolled in NIH-sponsored phase 3 clinical trials
 10), but our study shows that, in mixed-gender CV RCTs,
omen are still underrepresented. In conclusion, close moni-
oring by the NIH and the support of a federal mandate have
ot been successful in increasing the enrollment of women in
ardiovascular RCTs. Investigation of the reasons for female
nder-representation warrants ongoing research.
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APPENDIX
or a supplementary table with a list of included phase 3 or 4 cardiovas-
ular randomized controlled trials sponsored by the NHLBI published
etween 1997 and 2006 with primary outcomes of MI, stroke, or death,
scular Randomized Cardiovascular Trials From 1997 to 2006
s it studies (CHF  congestive heart failure, CAD  coronary artery disease,
otes that subgroup analyses based on gender were published in the primary
t, and the dashed line represents the average enrollment of women over 10rdiova
roces
e den
rollmenlease see the online version of this article.
